Dr. Yadav on Olaparib/Neratinib in HER2-Overexpressing Uterine Serous Carcinoma

Ghanshyam Yadav, MD
Published: Thursday, Mar 28, 2019



Ghanshyam Yadav, MD, first-year resident, Baylor College of Medicine, discusses the combination of olaparib (Lynparza) and neratinib (Nerlyx) in patients with HER2-overexpressing uterine serous carcinoma.

Uterine serous carcinoma is highly resistant to chemotherapy, says Yadav. A lot of research is examining cell-surface targeting. Much of the research Yadav has done has involved using TKIs in uterine serous cancers. Yadav and colleagues hypothesized that combining a TKI, which targets the ERBB2 pathway, with olaparib, which targets the DNA damage repair pathway, could have synergistic activity in this patient population.

Treatment with a PARP inhibitor was found to increase the HER2 expression on the surface of the cells, providing more of a target for neratinib, explains Yadav. Moreover, cells that had been treated with neratinib increased the active component of PARP. In the mouse study, the combination proved to be synergistic with significantly longer survival benefit and a statistically significant difference in tumor growth in one of the cell lines, says Yadav.
SELECTED
LANGUAGE


Ghanshyam Yadav, MD, first-year resident, Baylor College of Medicine, discusses the combination of olaparib (Lynparza) and neratinib (Nerlyx) in patients with HER2-overexpressing uterine serous carcinoma.

Uterine serous carcinoma is highly resistant to chemotherapy, says Yadav. A lot of research is examining cell-surface targeting. Much of the research Yadav has done has involved using TKIs in uterine serous cancers. Yadav and colleagues hypothesized that combining a TKI, which targets the ERBB2 pathway, with olaparib, which targets the DNA damage repair pathway, could have synergistic activity in this patient population.

Treatment with a PARP inhibitor was found to increase the HER2 expression on the surface of the cells, providing more of a target for neratinib, explains Yadav. Moreover, cells that had been treated with neratinib increased the active component of PARP. In the mouse study, the combination proved to be synergistic with significantly longer survival benefit and a statistically significant difference in tumor growth in one of the cell lines, says Yadav.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x